These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19666619)

  • 41. Treatment of hepatitis C: a decision that needs careful consideration.
    Wright TL
    Am J Med; 1999 Aug; 107(2):180-1. PubMed ID: 10460052
    [No Abstract]   [Full Text] [Related]  

  • 42. New hepatitis C therapies.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
    [No Abstract]   [Full Text] [Related]  

  • 43. [IL-28B polymorphism and hepatitis C: impact on viral clearance--prolonged, spontaneous and after treatment with antiviral drugs].
    Halfon P; Cacoub P
    Rev Med Interne; 2011 May; 32(5):271-4. PubMed ID: 21126807
    [No Abstract]   [Full Text] [Related]  

  • 44. [Hepatitis C. An increase in interferon-free therapy].
    Warpakowski A
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():8. PubMed ID: 25026844
    [No Abstract]   [Full Text] [Related]  

  • 45. Designing a low-cost drug resistance database for viral hepatitis.
    Kuiken C
    Antivir Ther; 2010; 15(3 Pt B):517-20. PubMed ID: 20516573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'?
    Pécheur EI
    Gut; 2014 Jul; 63(7):1035-7. PubMed ID: 24092864
    [No Abstract]   [Full Text] [Related]  

  • 47. [New possibilities on the horizon for the treatment of hepatitis C virus infection: direct-acting antiviral therapy].
    Pár A
    Orv Hetil; 2010 Dec; 151(50):2045-56. PubMed ID: 21126947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis C virus therapies.
    Smith RE
    Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802
    [No Abstract]   [Full Text] [Related]  

  • 49. Bayesian network meta-analysis to evaluate interferon-free treatments in naive patients with genotype 1 hepatitis C virus infection.
    Trippoli S; Fadda V; Maratea D; Messori A
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):983-4. PubMed ID: 26114910
    [No Abstract]   [Full Text] [Related]  

  • 50. Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia.
    Giannini C; Petrarca A; Monti M; Arena U; Caini P; Solazzo V; Gragnani L; Milani S; Laffi G; Zignego AL
    Blood; 2008 Mar; 111(5):2943-5. PubMed ID: 18299456
    [No Abstract]   [Full Text] [Related]  

  • 51. Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
    Harrington PR; Deming DJ; Komatsu TE; Naeger LK
    Clin Infect Dis; 2015 Aug; 61(4):666-7. PubMed ID: 26002846
    [No Abstract]   [Full Text] [Related]  

  • 52. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
    Chen ZW; Hu P; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treating HCV in HIV 2013: on the cusp of change.
    Martel-Laferrière V; Dieterich DT
    Liver Int; 2014 Feb; 34 Suppl 1():53-9. PubMed ID: 24373079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New therapeutic options for hepatitis C.
    Waters L; Nelson M
    Curr Opin Infect Dis; 2006 Dec; 19(6):615-22. PubMed ID: 17075339
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse events raise concerns over safety of new hepatitis C drugs.
    McCarthy M
    BMJ; 2017 Jan; 356():j490. PubMed ID: 28137772
    [No Abstract]   [Full Text] [Related]  

  • 56. Virology of hepatitis B and C viruses and antiviral targets.
    Pawlotsky JM
    J Hepatol; 2006; 44(1 Suppl):S10-3. PubMed ID: 16338022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical timing and benefit of antiviral treatment for hepatitis C].
    Chen LC; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):164-169. PubMed ID: 28482401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A cyclic peptide mimic of an RNA recognition motif of human La protein is a potent inhibitor of hepatitis C virus.
    Manna AK; Kumar A; Ray U; Das S; Basu G; Roy S
    Antiviral Res; 2013 Mar; 97(3):223-6. PubMed ID: 23291201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
    Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
    J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
    [No Abstract]   [Full Text] [Related]  

  • 60. [Predictive factors of response to Direct Acting Antivirals therapy Drug resistance hepatitis C virus].
    Suda G; Yamasaki K; Sakamoto N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():189-92. PubMed ID: 26845928
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.